Therefore, multiple randomized controlled trials (RCTs) have investigated the efficacy of pharmacological agents, such as metformin, glucagon-like peptide 1 (GLP-1) analogs, and thiazolidinediones for delaying or even preventing the progression from prediabetes to diabetes [15–19]. This evidence concerns the gene GCG and prediabetes syndrome.